Publications by authors named "Liushun Feng"
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths. However, the HCC treatment is still challenging. Herein, we aimed to reveal the anti-tumor effect of Jolkinolide B in HCC cell lines Huh-7 and SK-Hep-1.
View Article and Find Full Text PDFBackground: Programmed cell death (PCD) functions critically in cancers and PCD-related genes are associated with tumor microenvironment (TME), prognosis and therapeutic responses of cancer patients. This study stratified hepatocellular carcinoma (HCC) patients and develop a prognostic model for predicting prognosis and therapeutic responses.
Methods: Consensus clustering analysis was performed to subtype HCC patients in The Cancer Genome Atlas (TCGA) database.
Background: The objective of the present study was to elaborate a flexible 915 MHz microwave antenna (F915 MMA) and to evaluate the safety and feasibility in laparoscopic hepatecyomy (LH).
Methods: The F915 MMA was redesigned based on the experiences in clinical practice. Ten porcine LHs were divided into a 'flexible' group and a control group, with 5 porcine LHs in each group.
Small-molecule Bcl-2/Bcl-xL inhibitor Navitoclax represents a promising cancer therapeutic since preclinical and clinical studies with Navitoclax have demonstrated strong anticancer activity in several types of cancers. However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated expression of Mcl-1 in hepatocellular carcinoma (HCC) and other cancers, posing a serious problem for its potential clinical utilities. Therefore, approaches that suppress the expression of Mcl-1 are urgently needed to overcome Navitoclax-resistance in these cancers.
View Article and Find Full Text PDFObjective: To study on the efficacy, prognosis and security of high-intensity focused ultrasound (HIFU) combined with transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC).
Methods: Totally 72 HCC patients treated by HIFU from December 2009 to January 2011 were divided into two groups according to treatment methods: 40 cases in HIFU group, 32 cases in TACE + HIFU treatment group (combined group). Then set up a control group include 40 cases treated by only TACE in the same period (TACE group).
Association studies on the X-ray repair cross-complementing group 1 (XRCC1) polymorphisms (Arg194Trp, Arg280His, and Arg399Gln) in hepatocellular carcinoma (HCC) have shown conflicting results. The aim of this study was to quantitatively summarize the evidence for such a relationship. Published literatures from PubMed, Embase, CNKI, and Chinese Biomedicine Database were retrieved.
View Article and Find Full Text PDFSmall-molecule cell-permeable Bcl-2/Bcl-xL antagonist ABT-737 has recently emerged as a novel cancer therapeutic agent because it potently induces apoptosis in certain cancer cells. However, since ABT-737 binds to Mcl-1 with low affinity, ABT-737-mediated apoptosis signaling is inhibited in hepatocellular carcinoma (HCC) cells and other solid cancer cells due to the elevated expression of Mcl-1. Accordingly, strategies that target Mcl-1 are explored for overcoming ABT-737-resistance.
View Article and Find Full Text PDFNecessity and indications of invasive treatment for Budd-Chiari syndrome.
Hepatobiliary Pancreat Dis Int
June 2011
Background: The development of collaterals in Budd-Chiari syndrome has been described and these collaterals play an important role in the presentation of this disease. These collaterals are diagnostic and their use in management strategy has never been evaluated. This study aimed to investigate the indications, feasibility and necessity of invasive treatment for patients with Budd-Chiari syndrome and to determine whether such a strategy is necessary for optimal management.
View Article and Find Full Text PDFBreviscapine alleviates hepatic injury and inhibits PKC-mRNA and its protein expression in brain-dead BA-Ma mini pigs.
Hepatobiliary Pancreat Dis Int
December 2007
Article Synopsis
- Brain-dead donors can affect organ function post-transplantation, leading to liver injury, which this study investigates using BA-Ma mini pigs.
- The study involved three groups: a brain-dead group, a breviscapine-treated group, and a control group, measuring various liver injury markers and inflammatory factors at different time intervals.
- Results showed that breviscapine treatment reduced liver enzyme levels, inflammatory factors, and PKC-alpha expression, indicating its protective effects against hepatic injury after brain-death.
Combined splenocaval or mesocaval C shunt and portoazygous devascularization in the treatment of portal hypertension: analysis of 150 cases.
Hepatobiliary Pancreat Dis Int
February 2006
Background: Portal hypertension is a common disease and its major surgical therapeutic approaches include devascularization and shunting. This study was undertaken to investigate the effects of combined splenocaval or mesocaval C shunt and portoazygous devascularization (combined procedures) on portal hypertension.
Methods: The clinical data of 150 patients with portal hypertension who had undergone combined procedures at the First Affiliated Hospital of Zhengzhou University from May 1990 to May 2003 were analyzed retrospectively.
Triplex operation for portal hypertension with esophageal variceal bleeding: report of 140 cases.
Hepatobiliary Pancreat Dis Int
November 2004
Background: Portal hypertension is a common disease. The surgical therapy of this disease focuses on the resultant upper digestive tract bleeding, which can imperil patients' life directly. This study was to evaluate the effect of triplex operation (mesocaval C shunt with artificial graft, ligation of the coronary vein and splenic artery) on portal hypertension and its associated upper digestive tract bleeding.
View Article and Find Full Text PDFManagement of severe Budd-Chiari syndrome: report of 147 cases.
Hepatobiliary Pancreat Dis Int
November 2004
Article Synopsis
- Budd-Chiari syndrome (BCS) is a rare condition that leads to obstructed blood flow in the liver, and treatments mainly involve surgical or radiological methods.
- A study analyzed data from 147 severe BCS patients treated at a hospital over nine years, focusing on surgical outcomes.
- Results indicated that 69.4% of patients had excellent outcomes, while 27.2% had good results after various surgical interventions, with only five fatalities recorded during follow-up.
Surgical treatment of 1360 cases of Budd-Chiari syndrome: 20-year experience.
Hepatobiliary Pancreat Dis Int
August 2004
Background: Budd-Chiari syndrome (BCS) is a disease caused by blood flow obstruction of the main hepatic veins (MHVs) and/or the outlet of the inferior vena cava (IVC), characterized by retrohepatic portal hypertension (PHT) and/or IVC hypertension. In the past decade, over 3000 cases of BCS have been reported in China. This study was to sum up our 20-year experience in surgical treatment of BCS and to investigate its pathological classification and principles of surgery.
View Article and Find Full Text PDFDiagnosis and treatment of insulinoma: report of 105 cases.
Hepatobiliary Pancreat Dis Int
February 2002
Objective: To study the methods for diagnosis and treatment of insulinoma.
Methods: Clinical data from 105 patients with insulinoma who had been admitted to our hospital from July 1966 to December 1999 were retrospectively reviewed.
Results: Fasting blood glucose values were less than 2.